ALX ONCOLOGY HOLDINGS INC

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

ALXO$1.29+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	March 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$20,614	$17,567
Short-term investments	77,217	110,190
Prepaid expenses and other current assets	4,701	6,595
Total current assets	102,532	134,352
Property and equipment, net	2,703	2,905
Long-term investments	9,161	3,524
Other assets	6,504	6,994
Total assets	$120,900	$147,775
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,937	$4,497
Payable and accrued liabilities due to related party	48	149
Term loan, current	1,739	435
Accrued expenses and other current liabilities	13,018	13,419
Total current liabilities	18,742	18,500
Term loan, non-current	8,232	9,469
Other non-current liabilities	5,631	6,188
Total liabilities	32,605	34,157
Commitments and contingencies (Note 12)
Stockholders’ equity
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 53,384,145 and 53,052,912 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	53	53
Additional paid-in capital	740,000	734,412
Accumulated other comprehensive income	118	275
Accumulated deficit	(651,876)	(621,122)
Total stockholders’ equity	88,295	113,618
Total liabilities and stockholders’ equity	$120,900	$147,775

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.